UK Markets closed
  • NIKKEI 225

    26,165.59
    +638.22 (+2.50%)
     
  • HANG SENG

    26,588.20
    +102.00 (+0.39%)
     
  • CRUDE OIL

    44.81
    -0.10 (-0.22%)
     
  • GOLD FUTURES

    1,803.60
    -1.00 (-0.06%)
     
  • DOW

    30,046.24
    +454.97 (+1.54%)
     
  • BTC-GBP

    14,280.52
    +434.37 (+3.14%)
     
  • CMC Crypto 200

    377.31
    +7.56 (+2.04%)
     
  • Nasdaq

    12,036.79
    +156.15 (+1.31%)
     
  • ^FTAS

    3,633.35
    +51.07 (+1.43%)
     

Novartis CEO says Malaria drug is biggest hope against coronavirus - SonntagsZeitung

·1-min read

ZURICH (Reuters) - Novartis Chief Executive Vas Narasimhan said his Sandoz generics unit's malaria, lupus and arthritis drug hydroxychloroquine is the company's biggest hope against the coronavirus, Swiss newspaper SonntagsZeitung reported on Sunday.

Novartis has pledged to donate 130 million doses and is supporting clinical trials needed before the medicine, which U.S. President Donald Trump also has been promoting, can be approved for use against the coronavirus.

Other companies including Bayer and Teva have also agreed to donate hydroxychloroquine or similar drugs, while Gilead Sciences is testing its experimental drug remdesivir against coronavirus.

"Pre-clinical studies in animals as well as the first data from clinical studies show that hydroxychloroquine kills the coronavirus," Narasimhan told the newspaper. "We're working with Swiss hospitals on possible treatment protocols for the clinical use of the drug, but it's too early to say anything definitively."

He said the company is currently looking for additional active drug ingredients to make more hydroxychloroquine, should clinical trials be successful.

Narasimhan said three other Novartis drugs - Jakavi for cancer, multiple sclerosis drug Gilenya and fever drug Ilaris - are being studied for their effect on complications related to COVID-19, the newspaper reported. This follows separate efforts to re-purpose drugs made by companies including Roche and Sanofi to treat complications related to the disease.

For the original story click here: [https://bit.ly/2JluSbc]

Further company coverage [NOVN.S]

(Reporting by Zurich Newsroom; Editing by Muralikumar Anantharaman)